

Date and time: Tuesday 13 May 2014, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting **Diagnosis and monitoring of asthma**
9

Place: **Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ**

Present: John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric
Respiratory Medicine
Val Hudson, Patient member
Angela Key, Chief Respiratory Physiologist
Matthew Masoli, Consultant Respiratory Physician
Melanie McFeeters, Consultant Nurse in Children’s Respiratory
Diseases
Andrew Menzies-Gow (Chair), Consultant in Respiratory Medicine
Tahmina Siddiqui, General Practitioner partner
Michael Thomas, Professor of Primary Care Research & Principal in
General Practice (did not formally participate for item 3 regarding
FeNO but was present to answer questions at the request of the
Chair)
Emily Davies, Senior Research Fellow, NCGC
Alex Haines, Health Economist, NCGC
Rachel O’Mahony, Senior Research Fellow, NCGC (present for items
1-6)
Jill Parnham, Operations Director, NCGC
Amelia Unsworth, Project Manager, NCGC (notes)

Apologies: Tara Burn, Patient member
Ren Gilmartin, Respiratory Nurse Specialist
Bernard Higgins, Clinical Director, NCGC
Grace Marsden, Senior Health Economist, NCGC
Paul Miller, Senior Information Scientist, NCGC
Georgina Russell, RCP Clinical Fellow (Specialist Trainee Adviser)

In attendance:

NICE Staff:	Caroline Keir, Guidelines Commissioning Manager	
NICE attendee 1		

Observers:

--	--	--

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the ninth meeting of this GDG. Apologies were received from TB and RG.

The Chair reviewed and requested updates to the declarations of interest register.

AMG declared a personal pecuniary interest for giving two presentations to primary care on the use of Flutiform in asthma, sponsored by NAPP, and one presentation on specialist commissioning of severe asthma services, sponsored by Novartis. These were classified as a non-specific personal pecuniary interest. The guideline lead agreed that no further action was required.

MM declared a personal pecuniary interest for a spoken presentation at a severe asthma symposium sponsored by Novartis in March 2014. This was classified as a non-specific personal pecuniary interest. The Chair agreed that no further action was required.

No further declarations of interest were received and therefore no further action was required.

2. **GDG8 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Review linking evidence to recommendations**

The GDG reviewed the linking evidence to recommendations for FeNO for diagnosis, spirometry and history of atopic disorders. MT did not formally participate for the discussion on FeNO but was present to answer questions at the request of the Chair.

4. **Evidence review: signs and symptoms**

The GDG reviewed the evidence on the diagnostic accuracy of signs and symptoms.

5. **Evidence review: monitoring questionnaires**

The GDG reviewed the clinical and cost effectiveness evidence of validated questionnaires for monitoring asthma control.

6. **Evidence review: monitoring adherence**

The GDG reviewed the clinical and cost effectiveness evidence of monitoring adherence to treatment for asthma.

7. **HE model: preliminary results**

The GDG was given a presentation on the preliminary results of the health economic model for asthma diagnosis.

8. **Any other business**

None.

Date, time and venue of the next meeting

Notes

Monday 16 June 2014, 1000-1600 at NCGC, 180 Great Portland Street, London W1W
5QZ